Related references
Note: Only part of the references are listed.Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure Systematic Review of Observational Studies Involving 34 000 Patients
Dean T. Eurich et al.
CIRCULATION-HEART FAILURE (2013)
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies
Thomas Forst et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus
H. Qiu et al.
DIABETES OBESITY & METABOLISM (2013)
Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
J. Nagendran et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
O. J. Phung et al.
DIABETIC MEDICINE (2013)
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy
S. Wheeler et al.
DIABETOLOGIA (2013)
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
J. A. Hirst et al.
DIABETOLOGIA (2013)
Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011 Impact of the Introduction of Dipeptidyl Peptidase-4 Inhibitors
Takahide Kohro et al.
INTERNATIONAL HEART JOURNAL (2013)
Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Craig J. Currie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies
Bindiya Thakkar et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost Implications
Nihar R. Desai et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives Results from a large population-based follow-up study
Rikje Ruiter et al.
DIABETES CARE (2012)
Mortality After Incident Cancer in People With and Without Type 2 Diabetes Impact of metformin on survival
Craig J. Currie et al.
DIABETES CARE (2012)
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
R. J. Stevens et al.
DIABETOLOGIA (2012)
The Influence of Type 2 Diabetes and Glucose-Lowering Therapies on Cancer Risk in the Taiwanese
Ming-Chia Hsieh et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes
Christopher Ll Morgan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Davide Soranna et al.
ONCOLOGIST (2012)
Insulin resistance: from bit player to centre stage
Gerald M. Reaven
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
A1C and Cardiovascular Outcomes in Type 2 Diabetes A nested case-control study
Danielle C. Colayco et al.
DIABETES CARE (2011)
Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: A large population-based study
Marta Baviera et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Mechanism of the mitogenic influence of hyperinsulinemia
Boris Draznin
DIABETOLOGY & METABOLIC SYNDROME (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Mitogenic action of insulin: friend, foe or 'frenemy'?
B. Draznin
DIABETOLOGIA (2010)
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
S. L. Bowker et al.
DIABETOLOGIA (2010)
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
C. Nordin
DIABETOLOGIA (2010)
Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction
Marianne Zeller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Craig J. Currie et al.
LANCET (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus
Adriaan Kooy et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie et al.
DIABETOLOGIA (2009)
Trends in the prevalence and incidence of diabetes in the UK: 1996-2005
E. L. Masso Gonzalez et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2009)
Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
E. Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review
Elizabeth Selvin et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study
H. T. Horsdal et al.
DIABETOLOGIA (2008)
Prevalence and anti hyperglycemic prescribing trends for patients with type 2 diabetes in Italy:: A 4-year retrospective study from national primary care data
Giampiero Mazzaglia et al.
PHARMACOLOGICAL RESEARCH (2008)
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-retated mortality
M. Monami et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration
Kristijan H. Kahler et al.
DIABETES CARE (2007)
Trends in outpatient prescription drug costs in diabetic patients in Germany. 1994-2004
Wolfgang Rathmann et al.
DIABETES CARE (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Mahvash Zakikhani et al.
CANCER RESEARCH (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase
BJ Davis et al.
DIABETES (2006)
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes
JA Johnson et al.
DIABETIC MEDICINE (2005)
Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction:: results from a nationwide French registry
N Danchin et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
The UGDP controversy - thirty-four years of contentious ambiguity laid to rest
TB Schwartz et al.
PERSPECTIVES IN BIOLOGY AND MEDICINE (2004)
Sulphonylurea action revisited - the post-cloning era
FM Gribble et al.
DIABETOLOGIA (2003)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
Metformin: An update
D Kirpichnikov et al.
ANNALS OF INTERNAL MEDICINE (2002)
Obesity and disease management: Effects of weight loss on comorbid conditions
JW Anderson et al.
OBESITY RESEARCH (2001)
Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction
A Halkin et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2001)
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
NJ Morrish et al.
DIABETOLOGIA (2001)
Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells
CL Lawrence et al.
DIABETOLOGIA (2001)
Glimepiride block of cloned ß-cell, cardiac and smooth muscle KATP channels
DK Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Improved endothelial function with metformin in type 2 diabetes mellitus
KJ Mather et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Vascular benefits of gliclazide beyond glycemic control
PE Jennings
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
Share Paper
